Approximately 30% of psoriasis (PsO) patients develop psoriatic arthritis (PsA), which can appear with mild, moderate, or severe PsO. Dermatologists are often the first health care providers to both screen and make the diagnosis.

News

News
Friday, June 10, 2016
Results from 3 Phase 3 studies, published in The New England Journal of Medicine, demonstrated the safety and efficacy of ixekizumab (Taltz) for the treatment of moderate to severe plaque psoriasis.
News
Thursday, June 9, 2016
Positive, top-line results from the second Phase 3 Oral Psoriatic Arthritis Trial (OPAL) Beyond study of tofacitinib citrate (Xeljanz) were recently released.
News
Thursday, June 2, 2016
Click here to see the answer.